LONDON--GlaxoSmithKline PLC (GSK.LN) Wednesday said the Phase-3 study for sirukumab, a human antibody designed for patients with severely active rheumatoid arthritis, met its two most important targets, and added that it is on track to submit the regulatory applications in the third quarter of 2016.

Sirukumab is being co-developed as part of a collaboration with Janssen Biologics in Ireland, said the bio-pharmaceutical company.

The main two end points showed that the inhibition of radiographic progression, or joint destruction, was significantly greater among sirukumab-treated patients, and that at least 20% improvement in rheumatoid arthritis signs and symptoms was achieved by more than half of patients at week 16, the company said.

Shares at 1120 GMT down 12 pence, or 0.8%, at 1450 pence valuing the company at 70.64 billion pounds ($102.4 billion).

Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga

(END) Dow Jones Newswires

June 08, 2016 07:37 ET (11:37 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.